The therapeutic landscape for hormone receptor-positive (HR+) advanced breast cancer (BC) is moving from generalized ...

“This dosing regimen patent reflects our commitment to enhancing our intellectual property portfolio,” said Brian Sullivan, CEO and Co-Founder of Celcuity. “With patent exclusivity for gedatolisib now ...